Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.08
AIQ's Cash to Debt is ranked lower than
94% of the 207 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.19 vs. AIQ: 0.08 )
Ranked among companies with meaningful Cash to Debt only.
AIQ' s Cash to Debt Range Over the Past 10 Years
Min: 0.01  Med: 0.07 Max: N/A
Current: 0.08
Equity to Asset -0.23
AIQ's Equity to Asset is ranked lower than
94% of the 190 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.62 vs. AIQ: -0.23 )
Ranked among companies with meaningful Equity to Asset only.
AIQ' s Equity to Asset Range Over the Past 10 Years
Min: -0.39  Med: -0.08 Max: 0.04
Current: -0.23
-0.39
0.04
Interest Coverage 1.48
AIQ's Interest Coverage is ranked lower than
92% of the 108 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 41.98 vs. AIQ: 1.48 )
Ranked among companies with meaningful Interest Coverage only.
AIQ' s Interest Coverage Range Over the Past 10 Years
Min: 0.32  Med: 1.62 Max: 2.07
Current: 1.48
0.32
2.07
F-Score: 5
Z-Score: 0.58
M-Score: -3.08
WACC vs ROIC
3.59%
21.65%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 8.41
AIQ's Operating margin (%) is ranked higher than
65% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.67 vs. AIQ: 8.41 )
Ranked among companies with meaningful Operating margin (%) only.
AIQ' s Operating margin (%) Range Over the Past 10 Years
Min: -29.35  Med: 9.35 Max: 15.03
Current: 8.41
-29.35
15.03
Net-margin (%) 0.78
AIQ's Net-margin (%) is ranked higher than
51% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.03 vs. AIQ: 0.78 )
Ranked among companies with meaningful Net-margin (%) only.
AIQ' s Net-margin (%) Range Over the Past 10 Years
Min: -32.43  Med: 0.77 Max: 4.23
Current: 0.78
-32.43
4.23
ROA (%) 0.65
AIQ's ROA (%) is ranked higher than
58% of the 207 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.78 vs. AIQ: 0.65 )
Ranked among companies with meaningful ROA (%) only.
AIQ' s ROA (%) Range Over the Past 10 Years
Min: -21.65  Med: 0.64 Max: 2.88
Current: 0.65
-21.65
2.88
ROC (Joel Greenblatt) (%) 20.81
AIQ's ROC (Joel Greenblatt) (%) is ranked higher than
68% of the 205 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -12.38 vs. AIQ: 20.81 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
AIQ' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -47.2  Med: 16.89 Max: 28.12
Current: 20.81
-47.2
28.12
Revenue Growth (3Y)(%) -0.60
AIQ's Revenue Growth (3Y)(%) is ranked lower than
61% of the 137 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.90 vs. AIQ: -0.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
AIQ' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -44.2  Med: -0.50 Max: 12.1
Current: -0.6
-44.2
12.1
EBITDA Growth (3Y)(%) -9.90
AIQ's EBITDA Growth (3Y)(%) is ranked lower than
69% of the 117 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.80 vs. AIQ: -9.90 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
AIQ' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -41.9  Med: -4.40 Max: 30
Current: -9.9
-41.9
30
» AIQ's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-08-06)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

AIQ Guru Trades in Q2 2015

Jim Simons 623,425 sh (+1.95%)
Howard Marks 4,756,491 sh (unchged)
» More
Q3 2015

AIQ Guru Trades in Q3 2015

Chuck Royce 33,500 sh (New)
Howard Marks 4,756,491 sh (unchged)
Jim Simons 599,360 sh (-3.86%)
» More
Q4 2015

AIQ Guru Trades in Q4 2015

Chuck Royce 40,000 sh (+19.40%)
Jim Simons 637,260 sh (+6.32%)
Howard Marks 4,756,491 sh (unchged)
» More
Q1 2016

AIQ Guru Trades in Q1 2016

Jim Simons 648,160 sh (+1.71%)
Howard Marks Sold Out
Chuck Royce 37,312 sh (-6.72%)
» More
» Details

Insider Trades

Latest Guru Trades with AIQ

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:NAS:VRML, NAS:CDNA, NAS:PMD, OTCPK:AVDX, AMEX:VNRX, OTCPK:PMSNF, NAS:CEMI, OTCPK:PRFMF, NAS:LNTH, OTCPK:EPGNF, OTCPK:MHTX, OTCPK:SYGWF, AMEX:PTN, OTCBB:INIS, OTCPK:SEOVF, NAS:CGIX, NAS:DRIO, OTCPK:CBIS, NAS:GENE, NAS:ROSG » details
Traded in other countries:AI6M.Germany,
Alliance HealthCare Services Inc along with its subsidiaries provides outpatient diagnostic imaging and radiation therapy services to hospitals and other healthcare providers on a shared-service and full-time service basis and through fixed-sites.

Alliance HealthCare Services Inc Its diagnostic imaging services include magnetic resonance imaging technology and positron emission tomography/computed tomography services that generate representations of the internal anatomy and convert them to film or digital media. The Company operates in two reportable segments, Imaging and Radiation Oncology. It offers non scan-based services, which comprise the use of imaging systems under a short-term contract. In addition, it provides radiation oncology services that include conventional beam therapy, 3-D conformal radiation therapy, intensity modulated radiation therapy, image guided radiation therapy, stereotactic radiosurgery, low dose rate brachytherapy, and high dose rate brachytherapy for the treatment of cancer; and stereotactic radiation oncology services. Further, the Company offers ancillary services, such as marketing support, education, training, and billing assistance. It provides imaging and therapeutic services through hospitals and clinics, independent imaging and radiation oncology centers, and other healthcare providers on a shared-service and full-time service basis, as well as provides services through fixed-sites, primarily to hospitals or health systems. It competes with RadNet, Inc., Center for Diagnostic Imaging. The Company is subject to federal and state government regulations. It is also subject to various environmental, health, and safety laws regulated by the government.

Ratios

vs
industry
vs
history
P/E(ttm) 18.06
AIQ's P/E(ttm) is ranked higher than
75% of the 92 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 29.99 vs. AIQ: 18.06 )
Ranked among companies with meaningful P/E(ttm) only.
AIQ' s P/E(ttm) Range Over the Past 10 Years
Min: 9.65  Med: 23.21 Max: 625
Current: 18.06
9.65
625
PE(NRI) 18.06
AIQ's PE(NRI) is ranked higher than
76% of the 91 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 29.19 vs. AIQ: 18.06 )
Ranked among companies with meaningful PE(NRI) only.
AIQ' s PE(NRI) Range Over the Past 10 Years
Min: 9.65  Med: 23.21 Max: 625
Current: 18.06
9.65
625
Price/Owner Earnings (ttm) 2.79
AIQ's Price/Owner Earnings (ttm) is ranked higher than
98% of the 60 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 32.99 vs. AIQ: 2.79 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
AIQ' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 2.49  Med: 7.56 Max: 200
Current: 2.79
2.49
200
P/S 0.14
AIQ's P/S is ranked higher than
98% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.12 vs. AIQ: 0.14 )
Ranked among companies with meaningful P/S only.
AIQ' s P/S Range Over the Past 10 Years
Min: 0.08  Med: 0.57 Max: 1.29
Current: 0.14
0.08
1.29
PFCF 11.21
AIQ's PFCF is ranked higher than
98% of the 62 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 26.66 vs. AIQ: 11.21 )
Ranked among companies with meaningful PFCF only.
AIQ' s PFCF Range Over the Past 10 Years
Min: 0.74  Med: 5.07 Max: 28.15
Current: 11.21
0.74
28.15
POCF 0.78
AIQ's POCF is ranked higher than
99% of the 77 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 17.46 vs. AIQ: 0.78 )
Ranked among companies with meaningful POCF only.
AIQ' s POCF Range Over the Past 10 Years
Min: 0.44  Med: 2.33 Max: 4.74
Current: 0.78
0.44
4.74
EV-to-EBIT 16.42
AIQ's EV-to-EBIT is ranked higher than
56% of the 96 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.18 vs. AIQ: 16.42 )
Ranked among companies with meaningful EV-to-EBIT only.
AIQ' s EV-to-EBIT Range Over the Past 10 Years
Min: -342.7  Med: 14.70 Max: 77.4
Current: 16.42
-342.7
77.4
EV-to-EBITDA 6.68
AIQ's EV-to-EBITDA is ranked higher than
83% of the 104 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 13.58 vs. AIQ: 6.68 )
Ranked among companies with meaningful EV-to-EBITDA only.
AIQ' s EV-to-EBITDA Range Over the Past 10 Years
Min: -18.1  Med: 6.20 Max: 10.2
Current: 6.68
-18.1
10.2
Current Ratio 1.25
AIQ's Current Ratio is ranked lower than
85% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.85 vs. AIQ: 1.25 )
Ranked among companies with meaningful Current Ratio only.
AIQ' s Current Ratio Range Over the Past 10 Years
Min: 1  Med: 1.56 Max: 2.87
Current: 1.25
1
2.87
Quick Ratio 1.25
AIQ's Quick Ratio is ranked lower than
79% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.41 vs. AIQ: 1.25 )
Ranked among companies with meaningful Quick Ratio only.
AIQ' s Quick Ratio Range Over the Past 10 Years
Min: 1  Med: 1.56 Max: 2.87
Current: 1.25
1
2.87
Days Sales Outstanding 53.86
AIQ's Days Sales Outstanding is ranked higher than
59% of the 158 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 63.75 vs. AIQ: 53.86 )
Ranked among companies with meaningful Days Sales Outstanding only.
AIQ' s Days Sales Outstanding Range Over the Past 10 Years
Min: 41.3  Med: 48.80 Max: 56.49
Current: 53.86
41.3
56.49
Days Payable 26.02
AIQ's Days Payable is ranked lower than
83% of the 158 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 56.90 vs. AIQ: 26.02 )
Ranked among companies with meaningful Days Payable only.
AIQ' s Days Payable Range Over the Past 10 Years
Min: 18.28  Med: 25.63 Max: 32.25
Current: 26.02
18.28
32.25

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 0.27
AIQ's Price/Projected FCF is ranked higher than
99% of the 72 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.12 vs. AIQ: 0.27 )
Ranked among companies with meaningful Price/Projected FCF only.
AIQ' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.17  Med: 0.77 Max: 4.31
Current: 0.27
0.17
4.31
Price/Median PS Value 0.25
AIQ's Price/Median PS Value is ranked higher than
91% of the 171 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.94 vs. AIQ: 0.25 )
Ranked among companies with meaningful Price/Median PS Value only.
AIQ' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.19  Med: 1.05 Max: 3.71
Current: 0.25
0.19
3.71
Earnings Yield (Greenblatt) (%) 6.10
AIQ's Earnings Yield (Greenblatt) (%) is ranked higher than
80% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.80 vs. AIQ: 6.10 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
AIQ' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 1.3  Med: 6.30 Max: 11.2
Current: 6.1
1.3
11.2
Forward Rate of Return (Yacktman) (%) 73.79
AIQ's Forward Rate of Return (Yacktman) (%) is ranked higher than
98% of the 59 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.84 vs. AIQ: 73.79 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
AIQ' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -6.4  Med: 18.40 Max: 148.5
Current: 73.79
-6.4
148.5

More Statistics

Revenue (TTM) (Mil) $487.4
EPS (TTM) $ 0.36
Beta0.39
Short Percentage of Float5.09%
52-Week Range $5.88 - 19.81
Shares Outstanding (Mil)10.73
» More Articles for AIQ

Headlines

Articles On GuruFocus.com
Screening for Stocks Based on Price-to-Free Cash Flow Ratio Nov 18 2015 
Screening for Stocks Based on Price-to-Free Cash Flow Ratio Oct 20 2015 
Screening for Stocks Based on Price to Free-Cash Flow Ratio Sep 18 2015 
Alliance Imaging Inc. Reports Operating Results (10-K) Mar 14 2011 
Alliance Imaging Inc. Reports Operating Results (10-Q) Nov 05 2010 
Alliance Imaging Inc. (AIQ) CEO Paul S Viviano buys 10,000 Shares Aug 09 2010 

More From Other Websites
Alliance Oncology Partners with Saint Peter’s University Hospital Jun 21 2016
Luther W. Brady, M.D. Inducted into the Spanish Royal Academy of Medicine Jun 15 2016
ALLIANCE HEALTHCARE SERVICES, INC Files SEC form 8-K, Entry into a Material Definitive Agreement,... Jun 09 2016
Luther W. Brady, M.D. Awarded Seventh Honorary Degree Jun 07 2016
Alliance HealthCare Services to Present at LD Micro Invitational and Barclays 2016 High Yield Bond &... Jun 06 2016
Alliance HealthCare Services to Present at LD Micro Invitational and Barclays 2016 High Yield Bond &... Jun 06 2016
ALLIANCE HEALTHCARE SERVICES, INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements... May 25 2016
ETF’s with exposure to Alliance HealthCare Services, Inc. : May 19, 2016 May 19 2016
Alliance HealthCare Services, Inc. :AIQ-US: Earnings Analysis: Q1, 2016 By the Numbers May 17 2016
ALLIANCE HEALTHCARE SERVICES, INC Financials May 14 2016
Edited Transcript of AIQ earnings conference call or presentation 5-May-16 9:00pm GMT May 06 2016
Alliance HealthCare Services Reports Results for the First Quarter Ended March 31, 2016 May 05 2016
Alliance HealthCare Services Inc Earnings Call scheduled for 5:00 pm ET today May 05 2016
Alliance HealthCare Services Reports Results for the First Quarter Ended March 31, 2016 May 05 2016
Alliance HealthCare Services to Present at Upcoming B. Riley & Co. Annual Investor Conference May 05 2016
ALLIANCE HEALTHCARE SERVICES, INC Files SEC form 8-K, Results of Operations and Financial Condition,... May 05 2016
Alliance HealthCare Services to Present at Upcoming B. Riley & Co. Annual Investor Conference May 05 2016
Q1 2016 Alliance HealthCare Services Inc Earnings Release - After Market Close May 05 2016
ALLIANCE HEALTHCARE SERVICES, INC Files SEC form 10-K/A, Annual Report Apr 29 2016
Alliance HealthCare Services Schedules Conference Call for First Quarter 2016 Financial Results Apr 28 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)